Archive

May 29, 2025

Browsing

House Republicans are mounting a push to start a new select committee focused on investigating the Biden administration for allegedly ‘covering up’ signs of the 82-year-old former president’s decline.

Rep. Buddy Carter, R-Ga., is introducing legislation Thursday that would establish a panel of congressional investigators to ‘investigate and report upon the facts of President Joseph Robinette Biden, Jr.’s cognitive and physical health decline and the potential concealment of information from the American public,’ according to bill text obtained by Fox News Digital.

As of Thursday morning, the resolution had four co-sponsors in addition to Carter: Reps. Mark Alford, R-Mo., John Rose, R-Tenn., Derrick Van Orden, R-Wis., and Barry Moore, R-Ala.

Republicans have unleashed a tidal wave of scrutiny on the previous Democrat White House as new reports – as well as old concerns previously dismissed by mainstream media – surface about Biden’s mental state while in office and what lengths those closest to him took to allegedly hide it from others. 

Carter’s text calls to investigate former Vice President Kamala Harris and former first lady Jill Biden as well as whoever took part in keeping the audio tapes of Special Counsel Robert Hur’s interview with Biden from the public.

The select committee would also focus on whether Biden allies ‘concealed’ his prostate cancer diagnosis before it was announced publicly last week. 

Biden’s spokesperson denied prior knowledge of the diagnosis in a statement to the New York Times.

The resolution also specifically called for a probe into the use of the autopen in Biden’s White House to sign meaningful legislation.

‘This is potentially the biggest political scandal of our lifetime, and the American people deserve to know the truth about who was really running the White House during Biden’s tenure as president,’ Carter told Fox News Digital of his legislation.

‘From using the autopen to pardon his own family members to likely concealing a cancer diagnosis, our government must restore trust with the public by fully investigating the former administration’s lies and getting to the bottom of one of the most consequential coverups in history.’

Carter, who is currently running for Senate in Georgia, was among several Republicans who demanded Biden take a cognitive test last year.

‘The American people can no longer be left to wonder about their safety and security because of the President’s deteriorating mental state,’ Carter wrote in a June 2024 letter to the White House.

His new resolution comes on the heels of House Oversight Committee Chair James Comer, R-Ky., opening his own investigation into revelations surrounding Biden’s cognitive decline.

Comer spent much of the last Congress investigating whether Biden and his family unjustly profited from foreign cash.

The House Oversight chair sent letters to former senior White House aides, including Biden’s doctor, Kevin O’Connor, announcing a probe into ‘the role of former senior Biden White House officials in possibly usurping authority from former President Joe Biden and the ramifications of a White House staff intent on hiding his rapidly worsening mental and physical faculties.’

Meanwhile, first-term Rep. Jimmy Patronis, R-Fla., called for a similar select committee on Wednesday.

This post appeared first on FOX NEWS

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release.

The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire “substantially all” of 23andMe’s assets for $256 million.

The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for Chapter 11 bankruptcy protection in March.

23andMe said it will file a Form 25 Notification of Delisting with the SEC on or around June 6, which would subsequently remove the stock from listing and registering with the Nasdaq.

The company said the Nasdaq had originally informed the company that a Form 25 would be filed in March, but since the exchange has not yet submitted the filing, 23andMe is doing so voluntarily.

23andMe exploded into the mainstream because of its at-home DNA testing kits that allowed customers to examine their genetic profiles. At its peak, the company was valued at around $6 billion.

But after going public via a merger with a special purpose acquisition company in 2021, the company struggled to generate recurring revenue and stand up viable research or therapeutics businesses.

Regeneron’s deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. Pending approval, it’s expected to close in the third quarter of this year.

This post appeared first on NBC NEWS

Macy’s cut its full-year profit guidance on Wednesday even as it beat Wall Street’s quarterly earnings expectations, as the retailer’s CEO said it will hike prices of certain items to offset tariffs.

In a news release, the department store operator said it reduced its earnings outlook because of higher tariffs, more promotions and “some moderation” in discretionary spending. Macy’s stuck by its full-year sales forecast, however.

For fiscal 2025, Macy’s now expects adjusted earnings per share of $1.60 to $2, down from its previous forecast of $2.05 to $2.25. It reaffirmed its full-year sales guidance of between $21 billion and $21.4 billion, which would be a decline from $22.29 billion in the most recent full year.

In an interview with CNBC, CEO Tony Spring said about 15 cents to 40 cents per share of the guidance cut is due to tariffs. He said about 20% of the company’s merchandise comes from China.

Macy’s will raise some prices and stop carrying certain items to mitigate the hit from tariffs, he added.

“You’re dealing with it on both the demand side as well as the increased cost side,” he said. “And so navigating that, we have a series of different scenarios to try to figure out kind of what will be the reality, and we want our guidance to reflect the flexibility of that uncertainty, so that we can react in real time to how we serve or better serve the consumer.”

Spring said the company will be “surgical” with price changes.

“It’s not a one-size-fits-all kind of approach,” he said. “There are going to be items that are the same price as they were a year ago. There is going to be, selectively, items that may be more expensive, and there are items that we might not carry because the pricing doesn’t merit the quality or the perceived value by the consumer.”

Here’s how Macy’s did during its fiscal first quarter, compared with what Wall Street was anticipating, based on a survey of analysts by LSEG:

In the three-month period that ended May 3, the company’s net income was $38 million, or 13 cents per share, compared with $62 million, or 22 cents per share, in the year-ago period. Sales dropped from $4.85 billion in the year-ago quarter. Excluding some one-time charges including restructuring charges, adjusted earnings per share were 16 cents.

The company’s shares were down more than 2% in early trading on Wednesday.

Economic uncertainty — including President Donald Trump’s on-again, off-again tariff announcements — has complicated Macy’s turnaround plans. The New York City-based legacy retailer is more than a year into a three-year effort to become a smaller, but healthier business. It’s shuttering weaker stores and investing in stronger parts of the company, including luxury department store Bloomingdale’s and beauty chain Bluemercury. It has also tried to improve the customer experience, including by speeding up online deliveries and adding staff to stores.

Spring told analysts on the earnings call that the tariff impact on Macy’s outlook includes the additional costs of inventory previously imported under the 145% China tariffs, which have since dropped to 30%. He said the outlook does not include a potential increase in tariffs on the European Union or any other U.S. trading partner.

Trump recently threatened to implement, and then delayed, a 50% tariff on the EU.

Macy’s sells a mix of national band private brands, which are sold exclusively at its stores and on its website. Spring told CNBC that the company has reduced the share of its private brands that comes from China to about 27% — a drop from 32% last year and more than 50% before the Covid pandemic.

CFO Adrian Mitchell said on the company’s earnings call that Macy’s has taken action to blunt the impact of tariffs on national brands it sells, too. He said the company has renegotiated orders with vendors, canceled some orders and delayed others.

“We’ve been able to gain some vendor discounts, which has been helpful to us, but we’re absorbing some of that price as well,” he said.

And in some cases, Macy’s is keeping prices the same despite higher costs to appeal to value-conscious customers and gain market share from competitors, Mitchell added.

Spring said on the company’s earnings call on Wednesday that Macy’s sales were stronger in March and April compared to February, attributing some of that to improving weather. So far, sales trends in the second quarter have been above those in March and April, he added.

Macy’s plans to close about 150 underperforming namesake stores across the country by early 2027.

In the fiscal first quarter, Macy’s namesake brand remained its weakest. Comparable sales across Macy’s owned and licensed business, plus its online marketplace, declined 2.1% year over year.

When Macy’s took out the stores that it plans to shutter, however, trends looked slightly better. Comparable sales of its go-forward business, including its owned and licensed business and online marketplace, declined 1.9%

On the other hand, comparable sales at Bloomingdale’s rose 3.8% year over year, including its owned, licensed and marketplace businesses. Comparable sales at Bluemercury climbed 1.5% year over year.

To try to turn its namesake stores around, Macy’s has invested in 50 locations — dubbed the “First 50” — with more staffing, sharper displays and changes to its mix of merchandise. It has expanded that initiative to 75 additional stores, bringing the total to 125 locations that have gotten increased attention. That’s a little over a third of the 350 namesake locations that Macy’s plans to keep open.

Those 125 locations performed better than the overall Macy’s brand. Comparable sales among those revamped stores owned and licensed by Macy’s were down 0.8% compared with the year-ago period.

On Macy’s earnings call in March — before Trump made several sudden tariff moves that baffled companies and investors — Spring said the company’s guidance “assumes a certain level of uncertainty” about the economic outlook. He said even Macy’s affluent customer “is just as uncertain and as confused and concerned by what’s transpiring.”

Earlier this spring, Macy’s announced a few key leadership changes — including a new chief financial officer. Macy’s new CFO, Thomas Edwards, will begin on June 22. He previously served as the chief financial officer and chief operating officer of Capri Holdings, the parent company of Michael Kors. He will succeed Mitchell, who is leaving Macy’s.

As of Tuesday’s close, Macy’s shares are down about 29% so far this year. That trails the S&P 500′s nearly 1% gains during the same period. Macy’s stock closed on Tuesday at $12.04 per share, bringing the retailer’s market value to $3.35 billion.

This post appeared first on NBC NEWS

Dick’s Sporting Goods said Wednesday it’s standing by its full-year guidance, which includes the expected impact from all tariffs currently in effect.

The sporting goods giant said it’s expecting earnings per share to be between $13.80 and $14.40 in fiscal 2025 — in line with the $14.29 that analysts had expected, according to LSEG.

It’s projecting revenue to be between $13.6 billion and $13.9 billion, which is also in line with expectations of $13.9 billion, according to LSEG.

“We are reaffirming our 2025 outlook, which reflects our strong start to the year and confidence in our strategies and operational strength while still acknowledging the dynamic macroeconomic environment,” CEO Lauren Hobart said in a news release. “Our performance demonstrates the momentum and strength of our long-term strategies and the consistency of our execution.”

Here’s how the company performed in its first fiscal quarter compared with what Wall Street was anticipating, based on a survey of analysts by LSEG:

The company’s reported net income for the three-month period that ended May 3 was $264 million, or $3.24 per share, compared with $275 million, or $3.30 per share, a year earlier. Excluding one-time items related to its acquisition of Foot Locker, Dick’s posted earnings per share of $3.37.

Sales rose to $3.17 billion, up about 5% from $3.02 billion a year earlier.

For most investors, Dick’s results won’t come as a surprise because it preannounced some of its numbers about two weeks ago when it unveiled plans to acquire its longtime rival Foot Locker for $2.4 billion. So far, Dick’s has seen a mix of reactions to the proposed acquisition.

On one hand, Dick’s deal for Foot Locker will allow it to enter international markets for the first time and reach a customer that’s crucial to the sneaker market and doesn’t typically shop in the retailer’s stores. On the other hand, Dick’s is acquiring a business that’s been struggling for years and some aren’t sure needs to exist due to its overlap with other wholesalers and the rise of brands selling directly to consumers.

While shares of Foot Locker initially soared more than 80% after the deal was announced, shares of Dick’s fell about 15%.

The transaction is expected to close in the second half of fiscal 2025 and, for now, Dick’s outlook doesn’t include acquisition-related costs or results from the acquisition.

In the first full fiscal year post-close, Dick’s expects the transaction to be accretive to earnings and deliver between $100 million and $125 million in cost synergies.

This post appeared first on NBC NEWS